疏血通联合依达拉奉治疗急性脑梗死临床观察

目的观察疏血通联合依达拉奉治疗急性脑梗死的疗效和安全性。方法70例急性脑梗死患者按数字表法随机分成两组各35例，治疗组给予疏血通联合依达拉奉治疗，对照组给予舒血宁治疗，其他治疗相同。比较两组治疗前后欧洲脑卒中量表（ESS）和日常生活能力（ADL）评分的变化。结果两组治疗后ESS评分较治疗前均有改善（均P〈0．05），但治疗组改善更明显，与对照组比较差异有统计学意义（P〈0．05）；两组治疗后ADL评分均较治疗前上升（均P〈0．01），但治疗组上升更明显，与对照组比较差异有统计学意义（P〈0．05）。结论疏血通联合依达拉奉治疗急性脑梗死安全、有效。

Clinical observation of Shuxuetong injection combined with edaravone in treatment of acute cerebral infarction

Objective To observe the efficacy and safety of Shuxuetong injection combined with Edaravone in the treatment of acute cerebral infarction. Methods Seventy patients with acute cerebral infarction were randomly divided into two groups, the treatment group was given Shuxuetong injection and Edaravone, and the control group was treated by Shuxuening injection. Two groups were treated with routine therapy. ESS and ADL content changes in two groups were assessed at different point before treatment and two weeks after treatment. Results The score of ESS of two groups increased after treatment (P ＜ 0.05) ,but that in the Shuxuetong group was dramatically increased ,showing significantly different from that in the control group(P ＜0.05). ADL of the two groups improved after treatment(P ＜0.01) ,but the increase in the Shuxuetong group was significantly compared to the control group(P ＜0.05). Conclusion Shuxuetong injection combined with edaravone is an effective and safe medicine in treatment of acute cerebral infarction.